Curriculum Vitae

PERSONAL INFORMATION David Duguay

WORK EXPERIENCE

January 2018- Present Scientific Manager Health Canada (Canada)

August 2015-January 2018 Senior Scientific Evaluator Health Canada (Canada)

August 2011-August 2015 Scientific Evaluator Health Canada (Canada)

January 2012-December 2017 Invited Lecturer Universite Laval (Quebec) (Canada)

May 2011-December 2014 Lecturer Universite de Montreal (Canada)

December 2010-July 2011 Medical writer HIT Global (Canada)

May 2007-December 2010 Postdoctoral fellow Douglas Institute, Department of Psychiatry, McGill University (Canada)

EDUCATION AND TRAINING

September 2001-May 2007 Ph.D. Pharmacology Universite de Montreal (Canada)

September 1998-May 2001 B. Sc. (Hons) Biochemistry Universite du Québec a Montreal (Canada)

ADDITIONAL INFORMATION

Expertise Medicines evaluation; pharmacovigilance; safety and clinical evaluation of chemicals; cardiology; infectious diseases; pharmacology; epidemiology; pharmacoepidemiology; Phase I-III safety surveillance; Phase IV and post-market surveillance; Spontaneous reporting systems and databases; Drug utilisation; Risk communication; Risk management Publications Publications in the former Canadian Adverse Reaction Newsletter (CARN) 1.David Duguay, Djulus D & Springuel P. Cisplatin and aortic thrombosis. Canadian Adverse Reaction Newsletter, Volume 24 - Issue 3 July 2014. 2.David Duguay. Hydroxychloroquine and hypoglycaemia. Canadian Adverse Reaction Newsletter, Volume 24 - Issue 3 July 2014. Peer-reviewed journal articles 1.Yang Y, David Duguay, Fahrenkrug J, Cermakian N & Wing SS. USP2 regulates the intracellular localization of PER1 and circadian gene expression. Journal of Biological Rhythms. 2014;29(4):243-56. 2.Yang Y*, David Duguay*, Bédard N, Rachalski A, Baquiran G, Na CH, Fahrenkrug J, Storch K-F, Peng J, Wing SS & Cermakian N. Regulation of behavioral circadian rhythms and clock protein PER1 by the deubiquitinating enzyme USP2. Biol Open,

12/01/2021 European Medicine Agency Page 1/3 2012;1(8):789-801. * Authors contributed equally. 3.David Duguay, Bélanger-Nelson E, Mongrain V, Beben A, Khatchadourian A & Cermakian N Dynein light chain Tctex-type 1 modulates orexin signaling through its interaction with orexin 1 receptor. PLoS One 2011; 6, e26430. 4.Dufour CR, Levasseur M-P, Pham NH, Eichner LJ, Wilson BJ, Charest-Marcotte A, David Duguay, Poirier-Heon J-F, Cermakian N & Giguere V. Genomic convergence between ERR, PROX1 and BMAL1 in the control of metabolic clock outputs. PLoS genetics 2011; 7, e1002143. 5.Paquette PA, David Duguay, El- Ayoubi R, Menaouar A, Danalache B, Gutkowska J, DeBlois D & Mukaddam-Daher S. Control of Left Ventricular Mass by Moxonidine Involves Reduced DNA Synthesis and Enhanced DNA Fragmentation. British Journal of Pharmacology 2008; 153, 459-467. 6.David Duguay & deBlois, D. Differential regulation of caspases and MAPK activity underlies the rapid deletion of aortic smooth muscle cells by apoptosis and vascular remodeling in spontaneously hypertensive rats treated with amlodipine. British Journal of Pharmacology 2007; 151, 1315-1323. 7.David Duguay, Pesant S, Deschepper, CF & deBlois, D. Fibroblast apoptosis precedes cardiomyocytes mass reduction during left ventricular rremodeling in hypertensives rats treated with amlodipine. Journal of Hypertension 2007; 25, 1291-1299. 8.David Duguay, DerSarkissian S, Kouz R, Ongali B, Couture R & deBlois D. Kinin B2 receptor is not involved in enalapril-induced apoptosis and regression of hypertrophy in spontaneously hypertensive rat aorta: possible role of B1 receptor. British Journal of Pharmacology 2004; 141, 728-736. 9.Der Sarkissian S, Marchand E-L, David Duguay & deBlois D. Synergistic interaction between enalapril and nitric oxide enhancing therapy in the reduction of smooth muscle cell hyperplasia by apoptosis in hypertension. British Journal of Pharmacology 2004; 142, 912-918. 10.Der Sarkissian S, Marchand E-L, David Duguay, Hamet P, deBlois D. Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril. Cardiovascular Research 2003; 57, 775-83. Review article 1.David Duguay & Cermakian, N. The crosstalk between physiology and circadian clock proteins. Chronobiology International 2009; 8, 1479-1513. Book chapter 1.Hale T, David Duguay & deBlois, D. Apoptosis: molecular mechanisms in hypertension. In: Re RN, DiPette DJ, Schiffrin EL, Sowers JR (eds). Molecular mechanisms in hypertension. Abingdon: Taylor & Francis, 2006; pp 275-290. Projects Memberships Regulatory conferences attended (presenter, when indicated) 1.Canadian Pharmacovigilance and Risk Management Conference of the Drug Information Association (DIA), November 4, 2019. Gatineau, Canada. Oral presentation on Risk Management Plans for generic drugs in Canada. 2.Drug Information Association (DIA) Global meeting, June 23-27, 2019, San Diego. 3.13th Canadian meeting of the Drug Information Association (DIA), October 27-28, 2015. Ottawa. Oral presentation on Health Canada approach to signal detection from the safety literature. 4.Canadian Society of Hospital Pharmacists Professional Practice Conference, February 1-5, 2014, Toronto. Poster presentation on a signal assessment on antipsychotics and risk of venous thromboembolism. 5.HPFB International Pharmacovigilance Symposium, Ottawa, ON. Sept. 2013. 6.10th Canadian meeting of the Drug Information Association (DIA), November 6-7, 2012. Ottawa. 7.9th Canadian meeting of the Drug Information Association (DIA), November 1-2, 2011. Ottawa. Invited talks 1.S. Martin and David Duguay Use of Real World Evidence in Post-Market: Reassessing Canadas Risk Minimization Strategy for Isotretinoin Teratogenicity. Consideration of Real-World Evidence (RWE) Across the Drug Regulatory Life Cycle to Inform Decision-Making: Experiential Training/Learning Session 1, Health Canada, March 26, 2019. 2.David Duguay Careers outside academia. 2nd conference of the Canadian Society for Chronobiology. Concordia University, Montreal, 2015. 3.David Duguay, Yang Y, Baquiran G, Ouellet L, Storch K-F, Wing SS, Cermakian N. The deubiquitinating enzyme USP2 is involved in the regulation of circadian rhythms. Gordon conferences (Chronobiology), Newport, RI. July 2009. 4.David Duguay, Mongrain V, Beben A, Khatchadourian A, Cermakian N. Regulation of orexin receptor function: Identification, characterization and significance of interactions with protein partners. Douglas Mental Health University Institute, March 2008. 5.David Duguay, Sirois P, Nantel F, Battistini B, deBlois D. Aortic hypertrophy regression induced by enalapril is mediated by kinin B1 receptor dependent smooth muscle cell apoptosis induction in spontaneously hypertensive rats. Merck Frosst Pharmacology Research Day. October 2005. 6.David Duguay, Pesant S, deBlois D. Amlodipine initiates left ventricular hypertrophy (LVH) regression in the subepicardium of spontaneously hypertensive rats (SHR) by interstitial fibroblasts apoptosis. 15th European Meeting on Hypertension, Italy, June 2005. J hypertension, 2005 ; 23 (suppl. 2) :S237. 7.David Duguay, Sirois P, Nantel F, Battistini B, deBlois D. Kinin B1 receptors mediate smooth muscle cell apoptosis during vascular remodeling in spontaneously hypertensive rats treated with enalapril. 2005 Experimental Biology meeting abstracts [accessed at http://select.biosis.org/faseb], San Diego, CA, April 2005, FASEB Journal, 19, Abstract #629.15. 8.David Duguay, deBlois, D. Differential regulation of caspase and MAPK activity underlies the rapid deletion of aortic smooth muscle cells by apoptosis and vascular remodeling in spontaneously hypertensive rats treated with amlodipine. Scientific Sessions (AHA), New Orleans,

12/01/2021 European Medicine Agency Page 2/3 November 2004, Circulation, 2004;110 (suppl. III) III-276. 9.David Duguay, deBlois, D. Abrupt deletion of aortic smooth muscle cells by apoptosis precedes regression of vessel hypertrophy in spontaneously hypertensive rats treated with amlodipine. 25th annual Meeting of the Canadian hypertension Society, Calgary AB, Canada, October 2004. Can J Cardiol, 2004;20 (suppl. D). [Abstract #024 at http://www.pulsus.com/ccc2004/] 10.David Duguay, Kouz, R., Ongali, B., Couture, R., deBlois, D. Kinetics of enalapril-induced smooth muscle cell apoptosis and regression of aortic hypertrophy correlate with kinin B1 receptor up-regulation in spontaneously hypertensive rats (SHR). XIII Intern. Vascular Biology Meeting, Toronto, June 2004. Cardiovasc Pathology,2004; 13 (suppl. 1) :84. 11.David Duguay, deBlois, D. Amlodipine mediates onset regression of left ventricular hypertrophy (LVH) via selective deletion of non-cardiomyocytes by apoptosis in spontaneously hypertensive rats (SHR). 24th annual Meeting of the Canadian hypertension Society, Toronto ON, Canada, October 2003. Can J Cardiol, 2003;19 (suppl. A): 113A. 12.David Duguay, deBlois, D. Onset regression of left ventricular hypertrophy (LVH) by amlodipine is mediated by non-cardiomyocytes apoptosis in spontaneously hypertensive rats (SHR). 57th Annual Fall Conference and Scientific Sessions of the Council for High Blood Pressure Research, Washington, D.C., September 2003. Hypertension, 2003; 42: 389. 13.David Duguay, deBlois D Enalapril-induced regression of vascular hyperplasia in SHR does not imply the bradykinin B2 receptor. 23rd annual Meeting of the Canadian hypertension Society, Edmonton AB, Canada, October 2002. Can J Cardiol, 2002 ;18 (suppl. B) :180B. Other Relevant Information

12/01/2021 European Medicine Agency Page 3/3